The success of dupilumab, marketed by Sanofi under the name Dupixent, is evident in its remarkable $13 billion global sales achievement in 2024, marking a significant milestone for the company.

Fewer than 10% of children or adolescents with peanut allergy passed a desnsitiaztion food challenge after receiving dupilumab for 24 weeks. Image: Adobe Stock “The impact of the findings for ...

These runs all were done with the multimer version 2 model of Alphafold 2 in single sequence mode (i.e. no MSA was used) as a negative control, to highlight the importance of a quality MSA. The left ...

Each FASTA file contains the entire sequence of the subject scFv, a colon “:”, and then the candidate linear epitope which represents a small section of the target antigen protein that changes ...

They collected skin tape strips (STS) from the lesional and non-lesional skin of 20 patients with AD and 20 healthy volunteers (HV) over 16 weeks of dupilumab treatment. STS extracts were analyzed ...

Dupilumab, a human monoclonal antibody targeting for interleukin (IL)-4/13 receptor α chain, is widely applied in type 2 inflammation diseases treatment. This article reported two cases of refractory ...

Among other topics, Hudson discussed the success of Dupixent (dupilumab), highlighting that it has reached over $13bn in global sales, which affirms its commercial advantage and sets a milestone for ...

Dupilumab is under clinical development by Regeneron Pharmaceuticals and currently in Phase III for Bullous Pemphigoid. According to GlobalData, Phase III drugs for Bullous Pemphigoid does not have ...